Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : J&J Chairman Weldon's Salary Cut To $1 Million After Stepping Down As CEO

share with twitter share with LinkedIn share with facebook
share via e-mail
05/07/2012 | 11:51pm CET
   By Peter Loftus 

Johnson & Johnson (JNJ) Chairman William Weldon's annual base salary was reduced by nearly half to $1 million after he stepped down as chief executive last month, the company said Monday.

Weldon's previous annual base salary was set at $1.97 million for 2012, for his roles as both chairman and CEO, but with the expectation that J&J's board would consider the appropriate compensation for Weldon in his role as chairman only.

The decrease reflects that Weldon is no longer CEO, said spokesman Al Wasilewski.

On April 26, Alex Gorsky succeeded Weldon as CEO. Weldon is continuing as chairman and will remain an employee of the company, J&J said in a quarterly report filed with the Securities and Exchange Commission Monday.

J&J said in a previous SEC filing that in his role as chairman, Weldon will work closely with Gorsky to ensure a seamless leadership transition. During this time, all day-to-day management and operational responsibilities are being transferred to Gorsky.

Weldon will remain an employee but not a member of the J&J executive committee, which is the principal management group responsible for strategic operations and allocations of the resources of the company.

Weldon's main duties as chairman will include working with the board of directors, facilitating communication between the board and management, assisting Gorsky in business planning and strategy, representing the company before governmental and other organizations, and serving as chairman of the board's finance committee.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
09:18pOUTLOOK 2018 : A mother channels a loss unlike any other into a force to help ot..
11:17aABBVIE : Stocks’ Win Streak Extends to Six Days
02/16JOHNSON & JOHNSON : Stocks stretch winning streak to 6 days despite turbulence
02/16JOHNSON & JOHNSON : New tremfya® (guselkumab) data demonstrates long-term skin c..
02/16THE KLEIN LAW FIRM : Reminds Investors of an Investigation Concerning Possible V..
02/16EAT.MOVE.CONNECT. TIP : New website offers personalized cancer info, support
02/16JOHNSON & JOHNSON : Consumer presents new scientific research at 2018 american a..
02/16JOHNSON & JOHNSON : - ERLEADA, a Next-Generation Androgen Receptor Inhibitor Gra..
02/16JOHNSON & JOHNSON : williams, ronald a
02/16JOHNSON & JOHNSON : washington, a. eugene
More news
News from SeekingAlpha
02:07pRETIREMENT STRATEGY : How To Have Enough And Which Stocks To Own 
11:33aTHERAVANCE BIOPHARMA : Johnson & Johnson Deal Looks Solid 
02/17STOCKS TO WATCH : Retail Heavyweights To Center Stage 
02/17RETIREMENT STRATEGY : Inflation Is A Scourge On Retirees' Well-Being 
02/173 THINGS IN BIOTECH YOU SHOULD LEARN : February 17, 2018 
Financials ($)
Sales 2018 81 103 M
EBIT 2018 24 826 M
Net income 2018 19 539 M
Debt 2018 11 371 M
Yield 2018 2,76%
P/E ratio 2018 18,20
P/E ratio 2019 17,01
EV / Sales 2018 4,49x
EV / Sales 2019 4,13x
Capitalization 353 B
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 151 $
Spread / Average Target 15%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-7.19%352 552
NOVARTIS-3.37%224 301
PFIZER-2.84%212 857
ROCHE HOLDING LTD.-9.37%210 327
MERCK AND COMPANY-0.50%149 572
AMGEN3.23%133 277